[go: up one dir, main page]

CR9444A - Uso de modulares de canal de cloruro selectivos para tratar el abuso de alcohol y/o substancias estimulantes - Google Patents

Uso de modulares de canal de cloruro selectivos para tratar el abuso de alcohol y/o substancias estimulantes

Info

Publication number
CR9444A
CR9444A CR9444A CR9444A CR9444A CR 9444 A CR9444 A CR 9444A CR 9444 A CR9444 A CR 9444A CR 9444 A CR9444 A CR 9444A CR 9444 A CR9444 A CR 9444A
Authority
CR
Costa Rica
Prior art keywords
alcohol
modulars
relates
treat
stimulating substances
Prior art date
Application number
CR9444A
Other languages
English (en)
Inventor
Jose Legarda Ibanez Juan
Original Assignee
Hythiam Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hythiam Inc filed Critical Hythiam Inc
Publication of CR9444A publication Critical patent/CR9444A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invencion se refiere a metodos y tratamientos para usar composiciones farmaceuticas a partir de una clase de compuestos que modulan selectivamente, directa o indirectamente, la actividad del canal de cloruro GABAA, para tratar el abuso de alcohol y/o substancias estimulantes. La presente invencion tambien se refiere a metodos y protocolos para aliviar los sintomas asociados con el abuso del alcohol y/o substancias estimulantes en un plan de tratamiento compresivo.
CR9444A 2005-04-21 2007-10-16 Uso de modulares de canal de cloruro selectivos para tratar el abuso de alcohol y/o substancias estimulantes CR9444A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/111,435 US20050192271A1 (en) 2003-07-15 2005-04-21 Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse

Publications (1)

Publication Number Publication Date
CR9444A true CR9444A (es) 2008-02-20

Family

ID=37215204

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9444A CR9444A (es) 2005-04-21 2007-10-16 Uso de modulares de canal de cloruro selectivos para tratar el abuso de alcohol y/o substancias estimulantes

Country Status (17)

Country Link
US (3) US20050192271A1 (es)
EP (1) EP1742639B1 (es)
JP (1) JP2008536921A (es)
KR (1) KR20080004615A (es)
CN (1) CN101203225A (es)
AT (1) ATE539755T1 (es)
AU (1) AU2006240324B2 (es)
BR (1) BRPI0610038A2 (es)
CA (1) CA2605918A1 (es)
CR (1) CR9444A (es)
IL (1) IL186641A0 (es)
MX (1) MX2007012993A (es)
NO (1) NO20075562L (es)
NZ (1) NZ562585A (es)
RU (1) RU2007143053A (es)
WO (1) WO2006115743A2 (es)
ZA (1) ZA200709048B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
RU2468799C1 (ru) * 2011-08-03 2012-12-10 Общество с ограниченной ответственностью "Урал Крафт" Способ купирования алкогольного абстинентного синдрома посредством блокады бензодиазепиновых рецепторов
EP3057596A4 (en) * 2013-10-14 2017-03-29 Palmaya Pty Ltd Compositions and methods of administering same
US20200143922A1 (en) * 2016-06-03 2020-05-07 Yale University Methods and apparatus for predicting depression treatment outcomes
AU2019249277A1 (en) * 2018-04-06 2020-10-22 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of substance use disorders

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028611A (en) * 1989-06-29 1991-07-02 The Regents Of The University Of Minnesota Treatment for cocaine use
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
DE4123106A1 (de) * 1991-07-09 1993-01-14 Schering Ag Arzneimittel zur behandlung von entzugssymptomen
US5229120A (en) * 1992-02-05 1993-07-20 Devincent James F Treatment for cocaine abuse
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
GB9420010D0 (en) * 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
KR100596284B1 (ko) * 1998-03-31 2006-07-03 시오노기 앤드 컴파니, 리미티드 5-히드록시벤조[비]티오펜-3-카복실산 유도체의 제조 방법
WO1999061014A2 (en) 1998-05-28 1999-12-02 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6890951B2 (en) * 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
JP2002530339A (ja) * 1998-11-23 2002-09-17 セプラコール， インク． ２−ヒドロキシメチルオランザピン組成物及び方法
US6489341B1 (en) * 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6750235B1 (en) * 1999-09-30 2004-06-15 The General Hospital Corporation Pramipexole as a treatment for cocaine craving
EP1125579A3 (en) * 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
US20050192271A1 (en) 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
IL156798A0 (en) * 2001-01-17 2004-02-08 Hythiam Inc Use of flumazenil in developing a drug for the treatment of alcohol dependency
DK1378267T3 (da) * 2001-02-15 2007-10-08 Hythiam Inc Anvendelse af flumazenil til fremstilling af et medikament til behandling af kokainafhængighed
US20020150632A1 (en) * 2001-04-12 2002-10-17 Nick Scott Psychonutracological method for craving reduction in humans
FR2827172B1 (fr) * 2001-07-13 2004-07-02 Pf Medicament Derives de pyridin-2-yl-methylamine pour le traitement de la dependance aux opioides
US20030176456A1 (en) * 2001-12-21 2003-09-18 June Harry L. Methods for reducing alcohol cravings in chronic alcoholics
US6740677B2 (en) * 2002-08-19 2004-05-25 Hong Xue Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids
US20060058336A1 (en) * 2003-02-27 2006-03-16 Shigetada Nakanishi Pharmaceutical composition for treatment of drug dependence
AU2004247057A1 (en) * 2003-05-30 2004-12-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
JP2005332453A (ja) * 2004-05-19 2005-12-02 Hitachi Ltd 情報再生装置及び情報再生方法
US20060167723A1 (en) * 2005-01-21 2006-07-27 Berg L M Method of treating dependencies
EP1868593A2 (en) 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence

Also Published As

Publication number Publication date
EP1742639A2 (en) 2007-01-17
US20080207599A1 (en) 2008-08-28
WO2006115743A3 (en) 2007-06-28
US7863267B2 (en) 2011-01-04
EP1742639B1 (en) 2012-01-04
ATE539755T1 (de) 2012-01-15
KR20080004615A (ko) 2008-01-09
CA2605918A1 (en) 2006-11-02
MX2007012993A (es) 2008-03-11
NZ562585A (en) 2010-04-30
CN101203225A (zh) 2008-06-18
EP1742639A4 (en) 2008-05-07
BRPI0610038A2 (pt) 2016-11-29
AU2006240324A1 (en) 2006-11-02
NO20075562L (no) 2007-12-07
US20050192271A1 (en) 2005-09-01
WO2006115743A2 (en) 2006-11-02
IL186641A0 (en) 2008-06-05
ZA200709048B (en) 2008-09-25
AU2006240324B2 (en) 2010-02-25
JP2008536921A (ja) 2008-09-11
US20090215751A1 (en) 2009-08-27
RU2007143053A (ru) 2009-05-27

Similar Documents

Publication Publication Date Title
BRPI0508390B8 (pt) uso de um anticorpo antagonista anti-ngf, bem como kit e composição farmacêutica para tratamento de dor de câncer de osso
BRPI0908276B8 (pt) uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
NO20073068L (no) Stereoisomere anrikete 3-aminokarbonylbisykloheptenpyrimidindiaminforindelser og deres anvendelse
BRPI0510043A (pt) método de tratamento de dor neuropática usando antagonista de receptor crth2
AR083957A1 (es) Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
ATE554800T1 (de) Medizinische vorrichtungen mit porösen regionen zur kontrollierten aussetzung oder verabreichung therapeutischer wirkstoffe
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
CL2007002492A1 (es) Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras.
BRPI0907135B8 (pt) uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
EA201100020A1 (ru) Композиция для местного применения для лечения актинического кератоза
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
EA201001288A1 (ru) Лечение гипертонии 25-гидроксивитамином d3
CR9444A (es) Uso de modulares de canal de cloruro selectivos para tratar el abuso de alcohol y/o substancias estimulantes
BRPI0507645A (pt) anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico
CL2008003372A1 (es) Compuestos derivados de metil-bencimidazol, procedimiento de preparacion, composicion farmaceutica que los contiene y uso en el tratamiento y/o profilaxis de enfermedades afectadas por moduladores de fxr, en particular, dislipidemia, enfermedades de absorcion de colesterol y aterosclerosis, entre otras.
EA200870089A1 (ru) Применение производных бензоконденсированного гетероциклического сульфамида для лечения злоупотребления психоактивным веществом и аддикции
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)